Lantern Pharma, Inc.

36 articles with Lantern Pharma, Inc.

• Lantern Pharma Reports First Quarter 2021 Financial Results and Operational Highlights

  5/3/2021

  Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform oncology drug discovery and development today announced financial results for the first quarter ended March 31, 2021. 

• Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern's Artificial Intelligence Platform

  5/3/2021

  - Collaboration Will Leverage Lantern's RADR® A.I. Platform to Accelerate Development of Actuate's Drug Candidate, 9-ING-41 - Actuate's 9-ING-41 is a Best-In-Class Drug Candidate for Cancer & Fibrotic Diseases - Lantern Will Receive Equity Based on Meeting Development Milestones & May Receive Additional Equity Based on Use of Findings in Future Development

• Lantern Pharma Announces Publication Detailing Preclinical Results of Drug Candidate, LP-184, in a Spectrum of Drug-Resistant Lung Cancers in the Journal Oncotarget

  4/26/2021

  - Preclinical evidence supports the development of LP-184 in non-small cell lung cancers (NSCLC) for patients ineligible for targeted therapy - LP-184 shows nanomolar potency in in vitro lung cancer models that are resistant to other cancer drugs

• Lantern Pharma to Host First Quarter 2021 Operating and Financial Results Conference Call on May 3, 2021 at 4:30 p.m. ET

  4/26/2021

   Lantern Pharma (NASDAQ: LTRN) , a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to improve drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today that it will host a conference call

• Lantern Pharma to Participate in the Virtual 20th Annual Needham Healthcare Conference

  4/6/2021

  Lantern Pharma Inc. (NASDAQ: LTRN) , a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") platform to transform oncology drug discovery and development today announced that Panna Sharma , President and CEO of Lantern Pharma, will participate in the 20 th Annual Needham Healthcare Conference

• Lantern Pharma Expands Portfolio of Cancer Opportunities for LP-184 with ATRT Pediatric Brain Tumor Collaboration with Johns Hopkins

  4/1/2021

   Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform oncology drug discovery and development, today announced a collaboration with Johns Hopkins Pediatric Oncology Division of The Sidney Kimmel Comprehensive Cancer Center and Dr. Eric Raabe, M.D., Ph.D

• Lantern Pharma to Present New Data Supporting the Advancement of LP-184 at the AACR Virtual Annual Meeting 2021

  3/23/2021

  Lantern Pharma Inc. (NASDAQ: LTRN), will present new data on LP-184, a next-generation, targeted small molecule in the acylfulvene drug class, showcasing its potency across various 2D and 3D models of prostate cancer, at the American Association for Cancer Research (AACR) Virtual Annual Meeting, taking place from April 10-15, 2021.

• Lantern Pharma Announces Filing of Seven Patent Applications Globally on Novel DNA-Damaging Agent with Anticancer Properties

  3/17/2021

  Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") platform to transform oncology drug discovery and development today announced that it has filed seven patent applications globally on a novel DNA-damaging agent with anticancer properties.

• Lantern Pharma Interview to Air on Bloomberg TV in the US on the RedChip Money Report®

  3/12/2021

  Lantern Pharma Inc., a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence platform to transform oncology drug discovery and development, announced that an interview with CEO Panna Sharma will air on The RedChip Money Report® on Bloomberg TV in the US on Saturday, March 13, at 7 p.m. local time.

• Lantern Pharma Reports Fourth Quarter and Year End 2020 Financial Results and Operational Highlights

  3/10/2021

  Lantern Pharma Inc., a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence platform to transform oncology drug discovery and development announced financial results for the fourth quarter and fiscal year ended December 31, 2020.

• Lantern Pharma to Host Fourth Quarter and Fiscal Year End 2020 Operating and Financial Results Conference Call on March 10, 2021 at 4:00 p.m. ET

  3/3/2021

  Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") platform to improve cancer drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today that it will host a conference call

• Lantern Pharma Announces Closing of Public Offering of $69 Million USD and Full Exercise of Underwriter's Over-Allotment Option

  1/20/2021

  Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform cancer drug development and identify patients who will benefit from its targeted oncology therapeutics, today announced the closing of its previously announced public offering of 4,928,571 sha

• Lantern Pharma Announces Pricing of $60 Million Public Offering

  1/14/2021

  Lantern Pharma announced the pricing of a public offering of 4,285,715 shares of its common stock at a public offering price of $14.00 per share, for gross proceeds of $60 million, before deducting underwriting discounts and offering expenses.

• Lantern Pharma Announces Launch of Antibody Drug Conjugate (ADC) Program to Target Solid Tumors & Blood Cancers through Agreement with Califia Pharma

  1/4/2021

  - Lantern will evaluate and potentially develop ADC programs with novel patent protected linkers, drug payloads and conjugation processes from Califia that have demonstrated enhanced, highly targeted anti-tumor activity, creating new opportunities with Lantern's portfolio of DNA damage compounds - Lantern plans on evaluating and potentially launching additional programs with the ADC compounds and novel linker technologies in cancers where drug resistance is a key issue

• Lantern Pharma Announces Collaboration with World Leading Brain Cancer Program at Johns Hopkins to Further Develop LP-184 as Therapy for Glioblastoma

  12/17/2020

  Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform cancer drug development and identify patients who will benefit from its targeted oncology therapeutics, today announced a collaboration and research agreement with the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Kennedy Krieger Institute.

• Lantern Pharma Announces Upcoming Conference Presentations - Nov 24, 2020

  11/24/2020

  Lantern Pharma announced that Panna Sharma, CEO and President, will participate in the following investor events in December:

• Lantern Pharma Reports Third Quarter 2020 Financial Results & Continued Operational Progress

  10/29/2020

  Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary artificial intelligence ("A.I.") platform, RADR® , to transform oncology drug discovery and development, today announced financial results for the third quarter ended September 30, 2020.

• Lantern Pharma to Host Third Quarter 2020 Operating and Financial Results Conference Call on October 29, 2020 at 4:00 p.m. ET

  10/22/2020

  Lantern Pharma announced that it will host a conference call and live webcast on Thursday, October 29, 2020 at 4:00 p.m. ET to discuss financial and operating results for the third quarter ended September 30, 2020.

• Lantern Pharma Advances Prostate Cancer Drug Development Research Collaboration with Georgetown University for LP-184, a Next-Generation, Targeted DNA-Damaging Agent

  10/5/2020

  --  Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ®  artificial intelligence ("A.I.") platform to improve drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced the advancement of its collaboration with Georg

• Lantern Pharma Announces Collaboration and Research Agreement with Fox Chase Cancer Center Focused on Advancing the Development of LP-184 in Pancreatic Cancer

  9/22/2020

  Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR ® artificial intelligence ("A.I.") platform to improve drug discovery & development and identify patients who will benefit from its targeted oncology therapeutics, today announced a collaboration and research agreement with Fox Chase Cancer